Predict your next investment

CG Oncology company logo
HEALTHCARE | Drug Development
cgoncology.com

See what CB Insights has to offer

Founded Year

2010

Stage

Series D | Alive

Total Raised

$92.57M

Last Raised

$47M | 1 yr ago

About CG Oncology

CG Oncology is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of immunotherapies. The company's proprietary agent, CG0070, has the potential to deliver safe and effective cancer care alone and in combination with other immunotherapies.

CG Oncology Headquarter Location

400 Spectrum Center Drive Suite #2040

Irvine, California, 92618,

United States

949-288-6298

Latest CG Oncology News

CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Dec 20, 2021

- Company Receives $10 Million Milestone Payment from Kissei Pharmaceutical Co., Ltd. - December 20, 2021 08:00 AM Eastern Standard Time IRVINE, Calif.--( BUSINESS WIRE )--CG Oncology, Inc., a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, announced today it has triggered the first development milestone payment under its licensing agreement with Kissei Pharmaceutical Co., Ltd. for its oncology immunotherapy CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China. CG Oncology will receive a $10 million cash payment with the dosing of the first patient in Japan in the Phase 3 study (BOND3) for CG0070 as monotherapy for the treatment of patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). The goal of BOND3, an ongoing global Phase 3 trial which will enroll 110 patients, is to evaluate the safety and efficacy of CG0070 as a monotherapy for the treatment of NMIBC unresponsive to BCG. More information about the study can be found at www.clinicaltrials.gov (NCT04452591). About CG Oncology CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer. Our lead candidate, CG0070, is a selective oncolytic immunotherapy in a Phase 3 trial with CG0070 as a monotherapy for the treatment of BCG-unresponsive NMIBC, and a combination Phase 2 study of CG0070 with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab), and additional indications in other solid tumors are being pursued with CG0070 in combination with other immune checkpoint inhibitors. At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide. Learn more at www.cgoncology.com . About Kissei Pharmaceutical Co., Ltd. Kissei is a Japanese pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide. Kissei is engaged in bringing new drugs into the world through drug discovery and licensing activities in the field of urology, nephrology/dialysis, and rare/intractable diseases, which are its focus fields. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CG Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CG Oncology is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

CG Oncology Patents

CG Oncology has filed 5 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Clusters of differentiation
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/20/2007

6/28/2011

Transcription factors, Radiation therapy, Virus families, Gene expression, Oncology

Grant

Application Date

8/20/2007

Grant Date

6/28/2011

Title

Related Topics

Transcription factors, Radiation therapy, Virus families, Gene expression, Oncology

Status

Grant

CG Oncology Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CG Oncology Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.